The abuse potential of the synthetic cannabinoid nabilone

Addiction

Volumn 105, Issue 3, 2010, Pages 494-503

  Ware, Mark A ^a   St Arnaud Trempe, Emmanuelle ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Abuse; Canada; Cannabinoid; Nabilone; Pain; Survey

Indexed keywords

ANALGESIC AGENT; ANTIEMETIC AGENT; CANNABINOID; DRUG DERIVATIVE; NABILONE; TETRAHYDROCANNABINOL;

ADDICTION; CANADA; HUMAN; INTRACTABLE PAIN; OFF LABEL DRUG USE; PATHOPHYSIOLOGY; REVIEW;

ANALGESICS; ANTIEMETICS; CANADA; CANNABINOIDS; HUMANS; OFF-LABEL USE; PAIN, INTRACTABLE; SUBSTANCE-RELATED DISORDERS; TETRAHYDROCANNABINOL;

EID: 76249132039     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2009.02776.x     Document Type: Article

References (57)

1. Lichtman A. H., Martin B. R. Cannabinoid tolerance and dependence. Handb Exp Pharmacol 2005 168 : 691 717.
2. Calabrese E. J. Addiction and dose response: the psychomotor stimulant theory of addiction reveals that hormetic dose responses are dominant. Crit Rev Toxicol 2008 38 : 599 617.
3. Calhoun S. R., Galloway G. P., Smith D. E. Abuse potential of dronabinol (Marinol). J Psychoact Drugs 1998 30 : 187 196.
4. Cesamet (CII) (Nabilone) Fact Sheet. Available at: http://www.valeant. com/fileRepository/mediaCenter/Cesamet-Fact-Sheet.pdf (accessed 9 October 2009).
5. Fabre L. F., McLendon D. The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety. J Clin Pharmacol 1981 21 : 377S.
6. Ahmedzai S., Carlyle D. L., Calder I. T., Moran F. Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Br J Cancer 1983 48 : 657 663.
7. Skrabek R. Q., Galimova L., Ethans K., Perry D. Nabilone for the treatment of pain in fibromyalgia. J Pain 2008 9 : 164 173.
8. Faugier J., Sargeant M. Sampling hard to reach populations. J Adv Nurs 1997 26 : 790 797.
9. Glass R. M., Uhlenhuth E. H., Hartel F. W., Schuster C. R., Fischman M. W. Single-dose study of nabilone in anxious volunteers. J Clin Pharmacol 1981 21 : 383S 96S.
10. Mendelson J. H., Mello N. K. Reinforcing properties of oral delta 9-tetrahydrocannabinol, smoked marijuana, and nabilone: influence of previous marijuana use. Psychopharmacology 1984 83 : 351 356.
11. Ward A., Holmes B. Nabilone. A preliminary review of its pharmacological properties and therapeutic use. Drugs 1985 30 : 127 144. (Pubitemid 15006000)
12. Tramer M. R., Carroll D., Campbell F. A., Reynolds D. J. M., Moore R. A., McQuay H. J. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001 323 : 1 8.
13. Ware M. A., Tawfik V. L. Safety issues concerning the medical use of cannabis and cannabinoids. Pain Res Manag 2005 10 : 31A 7A.
14. Nabilone (Cesamet) for chemotherapy-induced nausea and vomiting. Med Lett Drugs Ther 2006 48 : 103 104.
15. Davis M., Maida V., Daeninck P., Pergolizzi J. The emerging role of cannabinoid neuromodulators in symptom management. Support Care Cancer 2007 15 : 63 71.
16. Lemberger L., Rowe H. Clinical pharmacology of nabilone, a cannabinol derivative. Clin Pharmacol Therapeutics 1975 18 : 720 726.
17. Lemberger L., Rubin A., Wolen R., DeSante K., Rowe H., Forney R. et al. Pharmacokinetics, metabolism and drug-abuse potential of nabilone. Cancer Treat Rev 1982 9 : 17 23.
18. Stark P. The pharmacologic profile of nabilone: a new antiemetic agent. Cancer Treat Rev 1982 9 : 11 6.
19. Clark A. J., Lynch M. E., Ware M., Beaulieu P., McGilveray I. J., Gourlay D. Guidelines for the use of cannabinoid compounds in chronic pain. Pain Res Manag 2005 10 : 44A 6A.
20. Gourlay D. Addiction and pain medicine. Pain Res Manag 2005 10 : 38A 43A.
21. Williamson E. M., Evans F. J. Cannabinoids in clinical practice. Drugs 2000 60 : 1303 1314.
22. Robson P. Human studies of cannabinoids and medicinal cannabis. Handb Exp Pharmacol 2005 168 : 719 756.
23. Marijuana as medicine. Physicians for a Smoke-Free Canada. 2002 1-7. Available at: http://www.smoke-free.ca/eng-home/news-press-Jan23-2002.htm (accessed 9 October 2009).
24. Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol 2006 1 25.
25. Sajan A., Corneil T., Grzybowski S. The street value of prescription drugs. Can Med Assoc J 1998 159 : 139 142.
26. Thibaudeau C. Faut-il prescrire la mari? [Must he prescribe pot?] La Presse 18 April 1999.
27. Fayerman P. Marijuana-based spray hits patients' pains, not brains: Canada first in world to approve new treatment derived from cannabis. Vancouver Sun 21 June 2005 Sect. A1.
28. Hardy P. Dogs get more time than health. Pot should be fully legal. Times & Transcript 23 November 2004.
29. Olson G. Research shows potential for medical marijuana. Vancouver Courier 6 June 2005.
30. White D. C. Officials won't admit truth about marijuana. Cape Breton Post April 15 2003 Sect. A6.
31. Brown J. PEI Medical Society sounds the alarm: about Ottawa's approval of medical marijuana. Journal-Pioneer 14 November 2001 Sect. 1.
32. Day J. A smoky issue: islanders combat their illnesses by lighting up joints as the debate heats up over medicinal marijuana. Guardian 23 October 1999 Sect. A1.
33. Perreault M. Un médicament à base de cannabis en voie d'être approuvé au Canada. [A medication based on cannabis on track for approval in Canada.] La Presse 22 December 2004.
34. Malboeuf M.-C. Le pot qui soulage. [Pot relief. Prescription: inhale three times daily.] Prescription: inhaler trois fois par jour. La Presse 27 June 2000.
35. Adam M. Ottawa MDs won't handle marijuana: despite Ontario having largest number of federally approved users, doctors are cautious. Ottawa Citizen 12 July 2003 Sect. D1.
36. Mercure P. Du THC montréalais pour les Américains. [Montreal THC for Americans.] La Presse 17 May 2006.
37. Hadekel P. Pharma gets high returns on 'pot pills'. Gazette 26 May 2006 Sect. B1.
38. Dworkin B. Medical marijuana at odds with doctors' promise. Ottawa Citizen. 9 September 2003 Sect. A14.
39. Drug card for Nabilone. Available at: http://www.drugbank.ca/drugs/ DB00486 (accessed 9 October 2009).
40. Cesamet. 2004. Available at: http://www.swiftrx.com/quick-search.jsp? criteria=cesamet (updated April 2007, accessed 12 July 2007).
41. MacPherson P. Synthetic forms of THC in clinical treatment settings. Correctional Service of Canada. 2006. Available at: http://www.csc-scc.gc.ca/ text/pblct/forum/e142/e142g-e.shtml (accessed 16 May 2007).
42. Russo E. Cannabis and Pain Management. p. 6-13. 2003. Available at: http://www.cannabishealth.com/issue06/index.html (updated 8 May 2007, accessed 12 July 2007).
43. What is Bluelight?. Available at: http://www.bluelight.ru/vb/faq.php?faq= about#faq-what-is-bluelight (accessed 11 July 2007).
44. What is synthetic THC?. Available at: http://www.treatingyourself.com/ vbulletin/showthread.php?t=14696 (updated 21 June 2006, accessed 11 July 2007).
45. Cesamet. Available at: http://www.treatingyourself.com/vbulletin/ showthread.php?t=14006 (updated 21 June 2007, accessed 11 July 2007).
46. Cesamet or Nabilone synthetic THC. Available at: http://www.torontohemp. com/phpBB2/viewtopic.php?t=943&sid=34fe558a9ef522f4bb654f23bc151509 (updated 26 November 2006, accessed 11 July 2007).
47. Hi, from a newbie. Available at: http://www.torontohemp.com/phpBB2/ viewtopic.php?t=397 (updated 16 April 2007, accessed 11 July 2007).
48. Available at: http://enmasse.ca/forums/viewtopic.php?t=219&sid= labf15f2b22b44a84db48c2cb84681b1 (updated 28 April 2006J, accessed 11 July 2007).
49. Synthetic Marijuana Helps Cancer Patients. Available at: http://shoutwire.com/default.aspx?p=comments&id=44237 (updated 18 December 2006, accessed 11 July 2007).
50. Steffan & Janet Watkins' Blog. 2007. Available at: http://steffanwatkins.blogspot.com/2007/02/monday-february-12-2007.html (updated 12 February 2007, accessed 11 July 2007).
51. Canadian Centre for Substance Abuse. Prescription Drug Abuse FAQs. 2007. Available at: http://www.ccsa.ca/NR/rdonlyres/97FF14B5-0A10-43F6-94DF- 520458F8D505/0/ccsa0115192007.pdf (accessed 10 July 2007).
52. Cook D. A. Addiction and medications: Alberta Alcohol and Drug Abuse Commission (AADAC). 2004. June.
53. Conseil des Medicaments du Québec Étude sur l'usage de Cesamet et de Marinol. [Quebec Medicines Council Study on the use of Cesamet and Marinol.] CdM Express 2007 4 : 3 4.
54. Barendregt C., Van der Poel A., Van de Mheen D. Tracing selection effects in three non-probability samples. Eur Addict Res 2005 11 : 124 131.
55. Spiller H., Lorenz D. J., Bailiey E. J., Dart R. C. Epidemiological trends in abuse and misuse of prescription opioids. J Addict Dis 2009 28 : 130 136.
56. Hughes A. A., Bogdan G. M., Dart R. C. Active surveillance of abused and misused prescription opioids using poison center data: a pilot study and descriptive comparison. Clin Toxicol (Phila) 2007 45 : 144 151.
57. Budney A. J., Moore B. A. Development and consequences of cannabis dependence. J Clin Pharmacol 2002 42 : 28S 33S.